Filtered By:
Drug: Actos

This page shows you your search results in order of date. This is page number 5.

Order by Relevance | Date

Total 156 results found since Jan 2013.

Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone?
The Insulin Resistance Intervention After Stroke (IRIS) trial has reported that treating insulin resistance with the peroxisome proliferator –activated receptor γ agonist pioglitazone hydrochloride reduced recurrent stroke or myocardial infarction (MI) by about one-fourth compared with placebo (pioglitazone, 9.0% vs placebo, 11.8%; hazard ratio [HR], 0.76; 95% CI, 0.62-0.93) in 3876 patients with recent (<6 months) ischemic stroke or transient ischemic attack and insulin resistance but without diabetes, heart failure, or bladder cancer. Pioglitazone was also associated with less incident diabetes vs placebo (3.8% vs ...
Source: JAMA Neurology - November 1, 2017 Category: Neurology Source Type: research

Targeting Pioglitazone Therapy After Stroke or Transient Ischemic Attack
This secondary analysis of the Insulin Resistance Intervention After Stroke trial estimates the relative and absolute effectiveness of pioglitazone after ischemic stroke or transient ischemic attack in subgroups of patients defined by pretreatment risk for stroke or myocardial infarction.
Source: JAMA Neurology - November 1, 2017 Category: Neurology Source Type: research

Pioglitazone Prevents Stroke in Patients with a Recent TIA or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial.
Conclusions -Pioglitazone was effective for secondary prevention of ischemic stroke in non-diabetic patients with insulin resistance. Clinical Trial Registration -URL: http://www.clinicaltrials.gov. Unique identifier: NCT00091949. PMID: 29084736 [PubMed - as supplied by publisher]
Source: Circulation - October 30, 2017 Category: Cardiology Authors: Yaghi S, Furie KL, Viscoli CM, Kamel H, Gorman M, Dearborn J, Young LH, Inzucchi SE, Lovejoy AM, Kasner SE, Conwit R, Kernan WN, IRIS Trial Investigators Tags: Circulation Source Type: research

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited
In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.Neurosignals 2017;25:54 –73
Source: Neurosignals - October 25, 2017 Category: Neurology Source Type: research

Pioglitazone Improves Left Ventricular Diastolic Function in Subjects With Diabetes
CONCLUSIONS Pioglitazone improves whole-body and myocardial insulin sensitivity, LV diastolic function, and systolic function in T2D. Improved myocardial insulin sensitivity and diastolic function are strongly correlated.
Source: Diabetes Care - October 23, 2017 Category: Endocrinology Authors: Clarke, G. D.; Solis-Herrera, C.; Molina-Wilkins, M.; Martinez, S.; Merovci, A.; Cersosimo, E.; Chilton, R. J.; Iozzo, P.; Gastaldelli, A.; Abdul-Ghani, M.; DeFronzo, R. A. Tags: Epidemiology-Diabetes Complications Pathophysiology/Complications Source Type: research

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited
In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.Neurosignals 2017;25:54 –73
Source: Neurosignals - October 17, 2017 Category: Neurology Source Type: research

Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
PMID: 29038213 [PubMed - in process]
Source: Circulation - October 17, 2017 Category: Cardiology Authors: Young LH, Viscoli CM, Inzucchi SE, Kernan WN Tags: Circulation Source Type: research

Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
PMID: 29038212 [PubMed - in process]
Source: Circulation - October 17, 2017 Category: Cardiology Authors: Jin-Shan H, Xue-Bin L Tags: Circulation Source Type: research

Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
PMID: 29038211 [PubMed - in process]
Source: Circulation - October 17, 2017 Category: Cardiology Authors: Musso G, Cassader M, Gambino R Tags: Circulation Source Type: research

Depression in the Context of Medical Disorders: New Pharmacological Pathways Revisited.
In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used. PMID: 29041003 [PubMed - as supplied by publisher]
Source: Neuro-Signals - October 17, 2017 Category: Neurology Authors: Lang UE, Walter M Tags: Neurosignals Source Type: research

Smoking cessation and outcome after ischemic stroke or TIA
Conclusion: Cessation of cigarette smoking after an ischemic stroke or TIA was associated with significant health benefits over 4.8 years in the IRIS trial cohort.
Source: Neurology - October 16, 2017 Category: Neurology Authors: Epstein, K. A., Viscoli, C. M., Spence, J. D., Young, L. H., Inzucchi, S. E., Gorman, M., Gerstenhaber, B., Guarino, P. D., Dixit, A., Furie, K. L., Kernan, W. N., For the IRIS Trial Investigators Tags: Stroke prevention, Prognosis, All Cerebrovascular disease/Stroke, Infarction ARTICLE Source Type: research

IRIS: Best Candidates for Pioglitazone After Stroke IRIS: Best Candidates for Pioglitazone After Stroke
Stroke patients with insulin resistance who are at greatest risk for repeat stroke derive the greatest benefit from pioglitazone treatment.Medscape Medical News
Source: Medscape Today Headlines - September 26, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news

Antidiabetic drugs and stroke risk. Current evidence.
Abstract Cardiovascular disease (CVD) is the major cause of morbidity and mortality for individuals with type 2 diabetes (T2D). In particular, the risk for stroke is twice that of patients without diabetes, and diabetes may be responsible for >8% of first ischemic strokes. Therefore, the way to prevent stroke in these patients has become an important issue. Traditionally, glucose-lowering drugs had not been shown to protect against stroke. Moreover, several antidiabetic drugs (i.e., sulfonylureas, rosiglitazone) have been reported to be associated with increased risks of CVD and stroke. On the contrary, data on...
Source: European Journal of Internal Medicine - September 20, 2017 Category: Internal Medicine Authors: Castilla-Guerra L, Fernandez-Moreno MDC, Leon-Jimenez D, Carmona-Nimo E Tags: Eur J Intern Med Source Type: research

Cardioprotective effect of Phyllanthus amarus against high fructose diet induced myocardial and aortic stress in rat model.
The objective of this study is to investigate the cardio-protective activity of aqueous extract of Phyllanthus amarus (PAAE) against high-fructose (HF) diet induced cardiac damage in Wistar rats. Male Wistar rats were randomly assigned into five groups of six animals each: Control (C), Control treated with PAAE (C+PAAE), High fructose diet fed (F), High fructose diet fed treated with PAAE (F+PAAE) and High fructose diet fed treated with Pioglitazone (F+Pio). PAAE was orally administered at a dosage of 200mg/kg body weight/day to C+PAAE and F+PAAE group rats for 60days. Pioglitazone (10mg/kg body weight/day) was used to com...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - September 19, 2017 Category: Drugs & Pharmacology Authors: Putakala M, Gujjala S, Nukala S, Bongu SBR, Chintakunta N, Desireddy S Tags: Biomed Pharmacother Source Type: research

Which Patients With Ischemic Stroke and Insulin Resistance May Benefit From Pioglitazone?
The Insulin Resistance Intervention After Stroke (IRIS) trial has reported that treating insulin resistance with the peroxisome proliferator –activated receptor γ agonist pioglitazone hydrochloride reduced recurrent stroke or myocardial infarction (MI) by about one-fourth compared with placebo (pioglitazone, 9.0% vs placebo, 11.8%; hazard ratio [HR], 0.76; 95% CI, 0.62-0.93) in 3876 patients with recent (<6 months) ischemic stroke or transient ischemic attack and insulin resistance but without diabetes, heart failure, or bladder cancer. Pioglitazone was also associated with less incident diabetes vs placebo (3.8% vs ...
Source: JAMA Neurology - September 18, 2017 Category: Neurology Source Type: research